Mylan Pharmaceuticals and pharma alliances, Banner Pharmacaps have entered into a settlement and license agreement with Eisai and Valeant Pharmaceuticals.
It will resolve patent litigation related to Bexarotene Capsules, 75 mg.
Bexarotene is the generic version of TARGRETIN, which is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
Pursuant to the agreement of the pharma alliances, the pending litigation will be dismissed.
Mylan and Banner will receive a license to begin selling a generic version of the product on July 9, 2015.
All other terms and conditions of the settlement and license agreement are confidential.
View the full article at MarketWatch
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Mylan
Report: Partnering Deals and Alliances with Valeant Pharmaceuticals
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity